English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new, University of Michigan-led study analyzing data from more than 850 patients across the state of Michigan found a commercially available genomic test known as Decipher Biopsy may help identify patients who are at high risk of prostate cancer progression.
Tag: prostate cancer
Mount Sinai researchers develop novel therapy that could be effective in many cancers
New York, NY (July 23, 2021) — Mount Sinai researchers have developed a therapeutic agent that shows high effectiveness in vitro at disrupting a biological pathway that helps cancer survive, according to a paper published in Cancer Discovery , a…
Bidirectional impact of cardiovascular disease, cancer in Blacks focus of new AHA center
Cardiovascular disease and cancer, the nation’s top two killers, share common ground like obesity and chronic inflammation, as well as a disproportionate impact on Black Americans. A new American Heart Association-funded center at the Medical College of Georgia is working…
Prostate cancer treatment among black, white patients during pandemic
What The Study Did: This study included 647 patients with untreated nonmetastatic prostate cancer (269 patients during the pandemic and 378 from before the pandemic). During the initial COVID-19 lockdown, only 1% of Black men underwent prostatectomy, while 26% of…
MRI can cut overdiagnoses in prostate-cancer screening by half
Most countries have not introduced nationwide prostate-cancer screening, as current methods result in overdiagnoses and excessive and unnecessary biopsies. A new study by researchers at Karolinska Institutet in Sweden, which is published in The New England Journal of Medicine ,…
American Society for Radiation Oncology (ASTRO) to host Annual Meeting in Chicago 10/24-27
#ASTRO21 will be the first major medical conference in the city; a curated digital program also will be offered for remote attendees
New AI tech for early detection of prostate cancer
Artificial intelligence-powered diagnostic tool spots asymptomatic prostate cancer in seconds
Tool helps predicts who will respond best to targeted prostate cancer therapy
New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
Anti-androgen therapy can fuel spread of bone tumours in advanced prostate cancer
Miniature 3D bone-like tissue models show effects of anti-androgens
Multimodality care improves treatment outcomes for aggressive prostate cancer
Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study.
Mount Sinai Welcomes Robotic Prostate Surgery Pioneer Mani Menon, MD
Robotic prostate surgery pioneer Mani Menon, MD, is joining Mount Sinai and will serve as Chief of Strategy and Innovation in the Department of Urology for the Mount Sinai Health System. He will also serve as a Professor of Urology, Director of Education and Director of the Precision Prostatectomy Program in the Department of Urology at Icahn Mount Sinai and Center of Excellence for Prostate Cancer at The Tisch Cancer Institute.
Multimodality care improves treatment outcomes for aggressive prostate cancer
FINDINGS Men with high-risk prostate cancer with at least one additional aggressive feature have the best outcomes when treated with multiple healthcare disciplines, known as multimodality care, according to a UCLA study led by Dr. Amar Kishan, assistant professor of…
Reactive oxygen species (ROS): Key components in cancer therapies
The article by Dr. Biswa Mohan Sahoo et al. is published in Anti-Cancer Agents in Medicinal Chemistry, 2021
Study Sheds Light on Persistent Racial Disparities in Prostate Cancer Care in the United States
Black men most likely to benefit from advanced prostate cancer therapies are 11 percent less likely to get them than non-Black men. This happens despite apparent equal opportunities in obtaining health care services, a new study in American veterans shows.
Immunotherapy may be effective for subset of prostate cancer
Researchers report that about a quarter of localized prostate cancers may demonstrate immunologic traits that suggest a substantial number of patients with prostate cancer may benefit from immunotherapies.
Immunotherapy may be effective for subset of prostate cancer
Boston – In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called “hot” tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered…
BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.
PSMA-targeted radiotracer pinpoints metastatic prostate cancer across anatomic regions
Newly FDA-approved imaging agent now available for patients
Prostate cancer linked to obesity
An INRS team is investigating the relationship between body mass and the risk of developing cancer
Protein in prostate cancer may inhibit tumor growth
Research from the University of Georgia has identified a protein that appears to prevent the cancer from spreading to and colonizing the bone, providing a new target for future therapeutics.
Protein in prostate cancer may inhibit tumor growth
Researchers identified the protein responsible for cancer’s aggressiveness
Rutgers Cancer Institute of New Jersey Experts Available for Comment during Men’s Health Month
New Brunswick, N.J., June 7, 2021 – June is a special time of year focused on heightening the awareness of preventable health problems and encouraging early detection and treatment of disease for men. Diseases like prostate cancer, which is the…
Oncotarget: The drug sensitivity of hepatocellular cancer cells
‘Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months’
Mount Sinai identifies the causes of racial disparity in prostate cancer in a multi-institutional study
MEDIA ADVISORY Senior Author: Ash Tewari, MBBS, MCh, Professor and System Chairman of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Prostate Cancer…
Study finds lower mortality rate for men at high risk for death from prostate cancer who received early postoperative radiation therapy
In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery
ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate Cancer
New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 ASCO Annual Meeting press program highlights a promising new treatment option for individuals previously treated for metastatic castration-resistant prostate cancer (mCRPC).
AI outperforms humans in creating cancer treatments, but do doctors trust it? It depends!
The impact of deploying Artificial Intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.
Oncotarget: E6-specific inhibitors as therapeutics for HPV+ head and neck carcinomas
‘Head and neck squamous cell carcinomas (HNSCC) are heterogeneous tumors that arise in the upper respiratory tract and are the 6th most common cancer worldwide by incidence’
Oncotarget: Lung squamous cell carcinoma tumors reveal therapeutic alterations
Lung cancer is the leading cause of cancer-related deaths across the globe with more than 1.7 million deaths annually’
When should screening start for men with a family history of prostate cancer?
Some men reach the risk threshold to start screening up to 11 years sooner than guidelines recommend
SWOG researchers advance cancer care at virtual ASCO 2021
“SWOG always brings an impressive portfolio of work to the ASCO annual meeting,” said SWOG Chair Charles D. Blanke, MD, “and this year I’m particularly excited about the research our investigators are presenting because it includes results that are likely…
Cleveland Clinic Researchers Identify New Drug Target for Treating Aggressive Prostate Cancer
CLEVELAND: According to new findings published in Science Translational Medicine, Cleveland Clinic researchers have identified a promising drug target for treating and preventing aggressive, drug-resistant prostate cancer.
The team, led by Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, demonstrated that inhibiting the protein H6PD led to significantly reduced tumor sizes and improved survival among mouse models with drug-resistant prostate cancer. The H6PD levels also were elevated in biopsied patient tumors, suggesting the protein might be targeted in patients for treatment.
Cleveland’s University Hospitals Urology Institute offers alternative prostate cancer biopsy technique
University Hospitals offers a new technique called PrecisionPoint Transperineal Access System for obtaining a prostate biopsy. The hospital will also conduct a clinical trial to determine if it offers greater benefits than a traditional biopsy.
UVA develops new tools to battle cancer, advance genomics research
University of Virginia School of Medicine scientists have developed important new resources that will aid the battle against cancer and advance cutting-edge genomics research. UVA’s Chongzhi Zang, PhD, and his colleagues and students have developed a new computational method to…
Cleveland clinic researchers identify new drug target for treating aggressive prostate cancer
Findings published in Science Translational Medicine
Racemases: The hunt for drugs to neutralise these critical enzymes
Scientists from the University of Bath in the UK explore racemases and propose strategies for finding drugs that target these important enzymes.
Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…
Impact Journals to present on scientific integrity at SSP Annual Meeting
Impact Journals is an exhibitor/sponsor and will be presenting our scientific integrity process at the Society for Scholarly Publishing (SSP) Annual Meeting, occurring virtually from May 24-27, 2021
Researchers use environmental data to assess prostate cancer diagnosis factors
Environmental quality is associated with advanced-stage prostate cancer at diagnosis, according to a new study by University of Illinois Chicago researchers. Prostate cancer is up to 57% heritable, with the remainder attributed to environmental exposures. However, studies on those environmental factors and prostate cancer aggressiveness…
New insights into androgen’s action could boost battle against prostate cancer
Researchers at UVA Cancer Center have unveiled important new insights into how hormones known as androgens act on our cells – and the discovery could boost efforts to develop better treatments for prostate, ovarian and breast cancers. The findings shed…
Frontiers in Clinical Drug Research – Anti-Cancer Agents
Bentham Science has recently launched the new volume of the book, Frontiers in Clinical Drug Research – Anti-Cancer Agents. Frontiers in Clinical Drug Research – Anti-Cancer Agents is a book series essential for pharmaceutical scientists, postgraduate students and researchers seeking…
City of Hope opens Phase 2 trial to test if mushroom tablets could slow prostate cancer
Scientists investigate if City of Hope’s natural supplement derived from white button mushroom could lower prostate-specific antigen levels, an indicator of prostate cancer
Male bladder cancer vulnerability could lead to a new treatment approach
UC Davis Comprehensive Cancer Center researchers found that targeting androgen receptors – a type of protein specific to men – may destroy cancer cells. Focusing on this male protein variant common in malignant bladder tumor cells may serve as a new avenue for treating bladder cancer in men.
12 open arms in NCI-MATCH treatment trial await patients with advanced or rare cancers
A new study arm opens, expanding patients’ potential to qualify for the trial when they may not have other options; the available treatments target tumor defects with drugs that show efficacy evidence; testing labs continue to identify trial candidates
First clinical trials set for MRI cancer detection
Case Western Reserve University-developed imaging agent for MRI prostate cancer detection gets FDA approval for safety trials, set to begin in May in Columbus
New Urine-based Test Holds Promise for Detecting Aggressive Prostate Cancer
A new, urine-based test for aggressive prostate cancer being developed at the University of Michigan uses next-generation sequencing to assess 15 biomarkers to find cancer that can be missed by biopsies or imaging tests.
Novel drug regenerates erectile nerves damaged by prostate surgery
April 19, 2021–(BRONX, NY) –Researchers at Albert Einstein College of Medicine have developed a topical drug that regenerates and restores the function of erectile nerves damaged by radical prostatectomy, the most common treatment for localized prostate cancer. The drug was…
Bone microenvironment fosters breast cancer metastatic behavior
Two studies led by Baylor College of Medicine shed new light on the unanswered question of why estrogen receptor-positive (ER+) breast cancer sometimes grows back in the bone and spreads to other tissues despite effective endocrine therapies directed at ER.…
Study: New Approach May Boost Prostate Cancer Immunotherapies
Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body’s immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the U.S.
Study: New approach may boost prostate cancer immunotherapies
Strategy focuses on reprogramming tissues surrounding the tumor to help the body’s immune system attack the cancer